Transcriptional O
activation O
of O
the O
human B
interleukin I
- I
2 I
( I
IL I
- I
2 I
) I
gene I
, O
like O
induction O
of O
the O
IL B
- I
2 I
receptor I
alpha I
( I
IL I
- I
2R I
alpha I
) I
gene I
and O
the O
type O
1 O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
, O
is O
shown O
to O
be O
modulated O
by O
a O
kappa B
B I
- I
like I
enhancer I
element I
. O

Immunoglobulin B
gene I
- I
specific I
transacting I
factors I
have O
been O
shown O
to O
play O
a O
role O
in O
lymphoid O
tissue O
- O
specific O
expression O
of O
immunoglobulin B
genes I
. O

Molecules O
involved O
in O
the O
antigen O
receptor O
- O
dependent O
regulation O
of O
early B
T I
cell I
activation I
genes I
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T B
cell I
activation I
- I
specific I
enhancer I
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Functional O
silencer B
activity O
in O
vivo O
was O
associated O
with O
the O
presence O
of O
a O
specific O
silencer B
- I
DNA I
- I
protein I
complex I
in O
electrophoretic O
mobility O
shift O
assays O
with O
T O
- O
cell O
extracts O
. O

An O
apparent O
paradox O
is O
that O
the O
same O
sequence O
serves O
as O
an O
upstream B
promoter I
or I
enhancer I
element I
in O
a O
variety O
of O
housekeeping B
genes I
such O
as O
the O
histone B
H2B I
and I
U I
snRNA I
genes I
. O

The O
lymphoid B
cell I
specific I
octamer I
binding I
protein I
of O
60 O
kd O
( O
OTF B
- I
2A I
) O
specifically O
stimulates O
Ig B
promoters I
which O
consist O
essentially O
of O
a O
TATA B
- I
box I
and O
an O
octamer B
sequence I
upstream O
of O
it O
. O

Here O
we O
present O
evidence O
for O
yet O
another O
B B
cell I
specific I
octamer I
binding I
protein I
of O
75 O
kd O
( O
OTF B
- I
2B I
) O
. O

This O
analysis O
indicates O
that O
the O
75 O
kd O
- O
species O
OTF B
- I
2B I
is O
closely O
related O
to O
the O
60 B
kd I
species I
OTF I
- I
2A I
. O

Identification O
and O
purification O
of O
a O
human B
immunoglobulin I
- I
enhancer I
- I
binding I
protein I
( O
NF B
- I
kappa I
B I
) O
that O
activates O
transcription O
from O
a O
human B
immunodeficiency I
virus I
type I
1 I
promoter I
in O
vitro O
. O

The O
purified O
factor O
activated O
in O
vitro O
transcription O
of O
the O
human B
immunodeficiency I
virus I
type I
I I
promoter I
by O
binding O
to O
an O
upstream B
NF I
- I
kappa I
B I
- I
binding I
site I

This O
B B
cell I
- I
specific I
octamer I
- I
binding I
factor I
, O
in O
pure O
form O
, O
activated O
transcription O
from O
a O
kappa B
light I
chain I
promoter I
in O
vitro O
, O
thus O
demonstrating O
that O
it O
is O
indeed O
a O
B B
cell I
- I
specific I
transcription I
factor I
for O
this O
gene O
. O

Two O
B O
- O
cell O
- O
specific O
, O
cis B
- I
acting I
transcriptional I
regulatory I
elements I
have O
been O
identified O
. O

We O
report O
here O
the O
identification O
of O
a O
human B
B I
- I
cell I
nuclear I
factor I
( O
IgNF B
- I
A I
) O
that O
binds O
to O
DNA B
sequences I
in O
the O
upstream B
regions I
of O
both O
the O
mouse B
heavy I
and I
kappa I
light I
- I
chain I
gene I
promoters I
and O
also O
to O
the O
mouse B
heavy I
- I
chain I
gene I
enhancer I
. O

We O
report O
here O
the O
identification O
of O
a O
human B
B I
- I
cell I
nuclear I
factor I
( O
IgNF B
- I
A I
) O
that O
binds O
to O
DNA B
sequences I
in O
the O
upstream B
regions I
of O
both O
the O
mouse B
heavy I
and I
kappa I
light I
- I
chain I
gene I
promoters I
and O
also O
to O
the O
mouse B
heavy I
- I
chain I
gene I
enhancer I
. O

The O
ratios O
of O
nuclear O
to O
cytosolic B
hormone I
- I
receptor I
- I
complexes I
and O
of O
cytosolic O
activated O
to O
unactivated B
receptor I
complexes I
in O
intact O
cells O
are O
similar O
to O
Old O
World O
primates O
. O

Erythroid B
Kruppel I
- I
like I
factor I
( O
EKLF B
) O
is O
a O
red B
cell I
- I
specific I
transcriptional I
activator I
that O
is O
crucial O
for O
consolidating O
the O
switch O
to O
high O
levels O
of O
adult O
beta O
- O
globin O
expression O
during O
erythroid O
ontogeny O
. O

Fibrinogen B
activates O
NF B
- I
kappa I
B I
transcription I
factors I
in O
mononuclear O
phagocytes O
. O

Mononuclear O
phagocytes O
are O
exposed O
to O
fibrinous O
provisional O
matrix O
throughout O
migration O
into O
inflammatory O
foci O
, O
so O
this O
study O
was O
undertaken O
to O
determine O
whether O
fibrinogen O
triggers O
activation O
of O
NF B
- I
kappa I
B I
transcription I
factors I
. O

To O
determine O
the O
effects O
on O
transcriptional O
regulation O
, O
U937 O
cells O
were O
transfected O
with O
a O
plasmid O
containing O
the O
HIV B
- I
1 I
enhancer I
( O
bearing O
two O
NF B
- I
kappa I
B I
sites I
) O
coupled O
to O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter I
. O

OBJECTIVE O
: O
To O
identify O
and O
characterize O
estrogen B
receptor I
( I
ER I
) I
transcripts I
expressed O
in O
immune O
cells O
of O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
healthy O
donors O
. O

A O
small O
, O
nonpeptidyl O
mimic O
of O
granulocyte B
- I
colony I
- I
stimulating I
factor I
[ O
see O
commetns O
] O

A O
nonpeptidyl O
small O
molecule O
SB O
247464 O
, O
capable O
of O
activating O
granulocyte B
- I
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
signal O
transduction O
pathways O
, O
was O
identified O
in O
a O
high O
- O
throughput O
assay O
in O
cultured O
cells O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV O
- O
1 O
LTR O
- O
driven O
gene O
expression O
using O
herbimycin O
A O
and O
H7 O
. O

The O
identification O
of O
the O
mammalian B
sex I
- I
determining I
gene I
Sry I
has O
led O
to O
the O
discovery O
of O
a O
large O
family O
of O
related O
( O
' O
HMG B
box I
' O
) O
transcription B
factors I
that O
control O
developmental O
events O
in O
yeast O
, O
C O
. O
elegans O
, O
Drosophila O
and O
vertebrates O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

Human O
white O
blood O
cells O
and O
hair O
follicles O
are O
good O
sources O
of O
mRNA B
for O
the O
pterin B
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
for O
mutation O
detection O
. O

Pterin B
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
( O
PCD B
/ I
DCoH I
) O
is O
a O
protein O
that O
has O
a O
dual O
function O
. O

Biochemical O
characterization O
of O
the O
NF B
- I
Y I
transcription I
factor I
complex I
during O
B O
lymphocyte O
development O
. O

The O
transcription B
factor I
, O
NF B
- I
Y I
, O
plays O
a O
critical O
role O
in O
tissue O
- O
specific O
major B
histocompatibility I
complex I
class I
II I
gene I
transcription O
. O

Recombination O
of O
the O
MPC11 B
plasma I
B I
- I
cell I
derived I
NF I
- I
Y I
A I
: I
B I
: I
C I
complex I
with O
the O
low O
molecular O
mass O
protein O
fraction O
, O
NF B
- I
Y I
- I
associated I
factors I
( O
YAFs B
) O
, O
derived O
from O
mature O
A20 O
B O
- O
cell O
nuclei O
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF B
- I
Y I
as O
an O
intact B
trimeric I
complex I
. O

Functional O
blocking O
of O
E B
- I
selectin I
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
on O
endothelial O
cells O
with O
the O
corresponding O
mouse B
mAb I
significantly O
inhibited O
glucose O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
67 O
+ O
/ O
- O
16 O
, O
83 O
+ O
/ O
- O
12 O
, O
62 O
+ O
/ O
- O
8 O
versus O
144 O
+ O
/ O
- O
21 O
cells O
/ O
mm2 O
) O
. O

Functional O
blocking O
of O
E B
- I
selectin I
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
on O
endothelial O
cells O
with O
the O
corresponding O
mouse B
mAb I
significantly O
inhibited O
glucose O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
67 O
+ O
/ O
- O
16 O
, O
83 O
+ O
/ O
- O
12 O
, O
62 O
+ O
/ O
- O
8 O
versus O
144 O
+ O
/ O
- O
21 O
cells O
/ O
mm2 O
) O
. O

Confocal O
fluorescence O
microscopy O
studies O
showed O
that O
30 O
mM O
glucose O
induced O
an O
increase O
in O
endothelial O
surface O
expression O
of O
E B
- I
selectin I
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
. O

Confocal O
fluorescence O
microscopy O
studies O
showed O
that O
30 O
mM O
glucose O
induced O
an O
increase O
in O
endothelial O
surface O
expression O
of O
E B
- I
selectin I
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
. O

A O
5 B
. I
4 I
- I
kilobase I
mRNA I
, O
the O
expression O
of O
which O
is O
down O
- O
regulated O
after O
treatment O
of O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
various O
T O
cell O
- O
activating O
agents O
, O
was O
isolated O
using O
an O
mRNA O
differential O
display O
method O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

In O
the O
first O
set O
of O
experiments O
, O
IL B
- I
8 I
gene I
reporter I
constructs I
were O
used O
to O
transiently O
transfect O
a O
derivative O
( O
MVh2E1 O
- O
9 O
) O
of O
the O
HepG2 O
cell O
line O
which O
expresses O
P B
- I
4502E1 I
and O
metabolizes O
ethanol O
. O

Transient O
transfection O
of O
HeLa O
cells O
with O
chimeric B
plasmids I
containing O
wild B
- I
type I
or I
mutant I
SRR I
from O
the O
tissue B
factor I
promoter I
showed O
that O
intact B
Sp1 I
sites I
are O
necessary O
for O
basal O
promoter O
activity O
, O
whereas O
the O
integrity O
of O
Egr B
- I
1 I
sites I
was O
required O
for O
hypoxia O
- O
enhanced O
expression O
. O

Sequence O
analysis O
demonstrated O
that O
two O
NF B
- I
kappaB I
- I
like I
elements I
( O
1 O
and O
2 O
) O
were O
present O
in O
the O
regulatory B
region I
. O

Both O
NF B
- I
kappaB I
- I
like I
elements I
were O
able O
to O
bind O
to O
NF B
- I
kappaB I
or O
its O
related O
factor O
( O
s O
) O
in O
a O
Tax B
- O
dependent O
manner O
. O

Unlike O
typical O
NF B
- I
kappaB I
elements I
, O
the O
NF B
- I
kappaB I
- I
like I
elements I
in O
gp34 B
were O
not O
activated O
by O
treatment O
of O
Jurkat O
cells O
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF B
- I
kappaB I
- O
like O
binding O
activity O
. O

Chloramphenicol B
acetyltransferase I
reporter O
assays O
using O
the O
region O
upstream O
of O
the O
NF B
- I
kappaB I
- I
like I
elements I
identified O
an O
upstream O
region O
that O
reduced O
transcription O
from O
cognate B
and I
noncognate I
core I
promoters I
in O
a O
Tax O
- O
independent O
manner O
. O

Abeta B
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular B
signal I
- I
regulated I
kinase I
1 I
( O
ERK1 B
) O
and O
ERK2 B
in O
microglia O
and O
ERK2 B
in O
THP1 O
monocytes O
. O

Scavenger B
receptor I
and O
receptor B
for I
advanced I
glycated I
end I
products I
( O
RAGE B
) O
ligands O
failed O
to O
activate O
ERK B
and O
p38 B
MAPK I
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B
receptors I
and O
RAGE B
are O
not O
linked O
to O
these O
pathways O
. O

Exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta B
resulted O
in O
the O
activation O
of O
RSK1 B
and O
RSK2 B
and O
phosphorylation O
of O
cAMP B
response I
element I
- I
binding I
protein I
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta B
- O
induced O
changes O
in O
gene O
expression O

This O
presumed O
catfish B
STAT I
binds O
the O
mammalian B
interferon I
- I
gamma I
activation I
site I
, O
a O
known O
motif O
of O
mammalian O
STAT O
binding O
, O
as O
shown O
by O
electromobility O
shift O
assays O
. O

Purification O
of O
the O
proteins O
present O
in O
these O
DNA B
complexes I
confirms O
that O
the O
catfish O
reactive O
molecule O
binds O
to O
the O
interferon B
- I
gamma I
activation I
site I
sequence I
. O

Biochemical O
characterization O
of O
MIP B
- I
1 I
alpha I
nuclear I
protein I
. O

Bcl B
- I
3 I
is O
a O
proto B
- I
oncogene I
involved O
in O
the O
chromosomal O
translocation O
t B
( I
14 I
; I
19 I
) I
found O
in O
some O
patients O
with O
chronic O
lymphocytic O
leukemia O
. O

A O
synthetic O
peptide O
consisting O
of O
the O
Kaposi B
fibroblast I
growth I
factor I
signal I
sequence I
fused O
to O
the O
5 B
- I
lipoxygenase639 I
- I
656 I
bipartite I
nuclear I
localizing I
sequence I
has O
a O
prominent O
inhibitory O
effect O
on O
5 B
- I
lipoxygenase I
catalysis O
in O
granulocytic O
HL O
- O
60 O
cells O
activated O
by O
calcium O
ionophor O
A23187 O
. O

Inhibition O
of O
CD28 O
/ O
CD3 O
- O
mediated O
costimulation O
of O
naive O
and O
memory O
human O
T O
lymphocytes O
by O
intracellular O
incorporation O
of O
polyclonal B
antibodies I
specific O
for O
the O
activator B
protein I
- I
1 I
transcriptional I
complex I
. O

In O
response O
to O
stress O
, O
heat B
shock I
factor I
1 I
( O
HSF1 B
) O
acquires O
rapid O
DNA O
binding O
and O
transient O
transcriptional O
activity O
while O
undergoing O
conformational O
transition O
from O
an O
inert O
non B
- I
DNA I
- I
binding I
monomer I
to O
active O
functional O
trimers O
. O

We O
have O
used O
the O
hydrophobic B
repeats I
of O
the O
HSF1 B
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat B
shock I
factor I
binding I
protein I
1 I
( O
HSBP1 B
) O
, O
a O
novel O
, O
conserved O
, O
76 B
- I
amino I
- I
acid I
protein I
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B
repeats I
that O
interact O
with O
the O
HSF1 B
heptad I
repeats I
. O

We O
have O
used O
the O
hydrophobic B
repeats I
of O
the O
HSF1 B
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat B
shock I
factor I
binding I
protein I
1 I
( O
HSBP1 B
) O
, O
a O
novel O
, O
conserved O
, O
76 B
- I
amino I
- I
acid I
protein I
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B
repeats I
that O
interact O
with O
the O
HSF1 B
heptad I
repeats I
. O

To O
establish O
a O
biological O
role O
for O
HSBP1 B
, O
the O
homologous O
Caenorhabditis B
elegans I
protein I
was O
overexpressed O
in O
body O
wall O
muscle O
cells O
and O
was O
shown O
to O
block O
activation O
of O
the O
heat O
shock O
response O
from O
a O
heat B
shock I
promoter I
- I
reporter I
construct I
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV B
with O
protein B
serine I
- I
threonine I
phosphatase I
2A I
( O
PP2A B
) O
was O
identified O
in O
which O
PP2A B
dephosphorylates O
CaMKIV B
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B
signaling O
. O

Binding O
of O
the O
natural O
ligand O
stromal B
cell I
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
to O
CXCR4 B
, O
which O
inhibits O
entry O
of O
T O
- O
cell O
- O
tropic O
HIV O
- O
1 O
, O
activates O
also O
the O
ERK O
/ O
MAP B
kinase I
pathway O
. O

The O
bcl B
- I
6 I
proto I
- I
oncogene I
encodes O
a O
POZ B
/ I
zinc I
finger I
transcriptional I
repressor I
expressed O
in O
germinal O
center O
( O
GC O
) O
B O
and O
T O
cells O
and O
required O
for O
GC O
formation O
and O
antibody O
affinity O
maturation O
. O

The O
bcl B
- I
6 I
proto I
- I
oncogene I
encodes O
a O
POZ B
/ I
zinc I
finger I
transcriptional I
repressor I
expressed O
in O
germinal O
center O
( O
GC O
) O
B O
and O
T O
cells O
and O
required O
for O
GC O
formation O
and O
antibody O
affinity O
maturation O
. O

This O
signaling O
pathway O
may O
be O
crucial O
for O
the O
control O
of O
B O
- O
cell O
differentiation O
and O
antibody O
response O
and O
has O
implications O
for O
the O
regulation O
of O
other O
POZ B
/ I
zinc I
finger I
transcription I
factors I
in O
other O
tissues O
. O

The O
human B
DR3 I
gene I
, O
whose O
product O
is O
also O
known O
as O
Wsl B
- I
1 I
/ I
APO I
- I
3 I
/ I
TRAMP I
/ I
LARD I
, O
encodes O
a O
tumor B
necrosis I
factor I
- I
related I
receptor I
that O
is O
expressed O
primarily O
on O
the O
surface O
of O
thymocytes O
and O
lymphocytes O
. O

Finally O
, O
DR3 B
/ I
Wsl I
- I
1 I
protein I
expression O
is O
quite O
variable O
among O
these O
NB O
cell O
lines O
, O
with O
very O
low O
or O
undetectable O
levels O
in O
7 O
of O
17 O
NB O
cell O
lines O

Identification O
of O
human B
leukemic I
glucocorticoid I
receptors I
using O
affinity O
labeling O
and O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
. O

The O
presence O
of O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ B
3H I
] I
TA I
- I
receptor I
- I
antibody I
complexes I
to O
Protein B
A I
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 O
of O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
on O
sucrose O
gradients O
. O

Thus O
, O
the O
combination O
of O
affinity O
labeling O
and O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
is O
capable O
of O
providing O
direct O
physical O
identification O
of O
human B
lymphoid I
glucocorticoid I
receptors I
. O

1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
failed O
, O
however O
, O
to O
inhibit O
the O
activation O
of O
the O
T O
cell O
hybridomas O
by O
lectin B
or O
by O
an O
anti B
- I
Thy I
- I
1 I
antibody I
. O

Cotransfection O
of O
both O
c O
- O
Jun O
and O
c O
- O
Fos O
substitutes O
for O
B7 O
- O
1 O
costimulation O
in O
driving O
an O
activation B
protein I
- I
1 I
response I
element I
but O
not O
for O
the O
IL B
- I
2 I
promoter I
. O

To O
assess O
HUVEC O
activation O
, O
E B
- I
selectin I
expression O
was O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E B
- I
selectin I
- I
specific I
mRNA I
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF B
- I
kappa I
B I
, O
a O
transcription B
factor I
necessary O
for O
E B
- I
selectin I
gene I
activation O
. O

The O
heterodimeric O
Ku B
protein I
, O
which O
comprises O
a O
86 B
kDa I
( I
Ku86 I
) I
amd O
a O
70 B
kDa I
( I
Ku70 I
) I
subunits I
, O
is O
an O
abundant O
nuclear B
DNA I
- I
binding I
protein I
which O
binds O
in O
vitro O
to O
DNA B
termini I
without O
sequence O
specificity O
. O

Ku B
is O
the O
DNA B
- I
targeting I
component I
of O
the O
large O
catalytic B
sub I
- I
unit I
of O
the O
DNA B
- I
dependent I
protein I
kinase I
complex I
( O
DNA B
- I
PK I
[ I
CS I
] I
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double O
- O
strand O
break O
repair O
and O
lymphoid O
V O
( O
D O
) O
J O
recombination O
. O

Ku B
is O
the O
DNA B
- I
targeting I
component I
of O
the O
large O
catalytic B
sub I
- I
unit I
of O
the O
DNA B
- I
dependent I
protein I
kinase I
complex I
( O
DNA B
- I
PK I
[ I
CS I
] I
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double O
- O
strand O
break O
repair O
and O
lymphoid O
V O
( O
D O
) O
J O
recombination O
. O

Although O
the O
heterodimer B
Ku70 I
/ I
variant I
- I
Ku86 I
binds O
to O
DNA B
- I
ends I
, O
this O
altered O
form O
of O
the O
Ku B
heterodimer I
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic B
component I
of O
the O
complex O
, O
DNA B
- I
PK I
( I
CS I
) I
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA O
- O
PK O
activity O
in O
B O
cells O
. O

Although O
the O
heterodimer B
Ku70 I
/ I
variant I
- I
Ku86 I
binds O
to O
DNA B
- I
ends I
, O
this O
altered O
form O
of O
the O
Ku B
heterodimer I
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic B
component I
of O
the O
complex O
, O
DNA B
- I
PK I
( I
CS I
) I
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA O
- O
PK O
activity O
in O
B O
cells O
. O

Here O
we O
show O
that O
forced O
expression O
of O
the O
lung B
Kruppel I
- I
like I
transcription I
factor I
( O
LKLF B
) O
in O
Jurkat O
T O
cells O
is O
sufficient O
to O
program O
a O
quiescent O
phenotype O
characterized O
by O
decreased O
proliferation O
, O
reduced O
cell O
size O
and O
protein O
synthesis O
and O
decreased O
surface O
expression O
of O
activation O
markers O
. O

Although O
p12 B
( I
I I
) I
contains O
4 O
minimal O
proline O
- O
rich O
, O
src B
homology I
3 I
- I
binding I
motifs I
( O
PXXP B
) O
, O
a O
characteristic O
commonly O
found O
in O
proteins O
involved O
in O
signaling O
pathways O
, O
it O
has O
not O
been O
known O
whether O
p12 B
( I
I I
) I
has O
a O
role O
in O
modulating O
intracellular O
signaling O
pathways O
. O

METHODS O
: O
Flow O
cytometry O
, O
cell O
proliferation O
assays O
, O
and O
microscopy O
were O
used O
to O
track O
antigen B
following O
a O
single O
, O
intranasal O
dose O
of O
Alexa B
- I
488 I
labelled I
retinal I
antigen I
. O

Interleukin B
( I
IL I
) I
- I
18 I
has O
been O
well O
characterized O
as O
a O
costimulatory B
factor I
for O
the O
induction O
of O
IL B
- I
12 I
- I
mediated I
interferon I
( I
IFN I
) I
- I
gamma I
production O
by O
T O
helper O
( O
Th O
) O
1 O
cells O
, O
but O
also O
can O
induce O
IL O
- O
4 O
production O
and O
thus O
facilitate O
the O
differentiation O
of O
Th2 O
cells O
. O

To O
determine O
the O
mechanisms O
by O
which O
IL B
- I
18 I
might O
regulate O
these O
diametrically O
distinct O
immune O
responses O
, O
we O
have O
analyzed O
the O
role O
of O
cytokines B
in O
the O
regulation O
of O
IL B
- I
18 I
receptor I
alpha I
chain I
( O
IL B
- I
18Ralpha I
) O
expression O
. O

Inhibition O
of O
pro B
- I
inflammatory I
transcription I
factors I
such O
as O
activator B
protein I
( I
AP I
) I
- I
1 I
, O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
, O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
and O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

Inhibition O
of O
pro B
- I
inflammatory I
transcription I
factors I
such O
as O
activator B
protein I
( I
AP I
) I
- I
1 I
, O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
, O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
and O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

High O
- O
glucose O
- O
conditioned O
supernatant O
possessed O
an O
increased O
chemotactic O
activity O
for O
monocytes O
, O
which O
was O
neutralized O
by O
anti B
- I
MCP I
- I
1 I
antibody I
. O

The O
ability O
of O
interferon B
( I
IFN I
) I
- I
alpha I
to O
induce O
autoimmunity O
and O
exacerbate O
Th1 O
diseases O
is O
well O
known O
. O

BACKGROUND O
: O
Elevation O
of O
cellular O
cAMP O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
production O
and O
increases O
the O
expression O
of O
interleukin B
( I
IL I
) I
- I
10 I
in O
mononuclear O
cells O
. O

We O
identified O
PPAR B
- I
alpha I
and I
- I
gamma I
messenger O
RNA O
by O
RT O
- O
PCR O
and O
protein O
by O
immunoblotting O
of O
lysates O
of O
peritoneal O
macrophages O
and O
monocytic O
U937 O
cells O
. O

Using O
immunocytochemistry O
, O
we O
localized O
PPAR B
- I
alpha I
and I
- I
gamma I
within O
the O
nuclei O
of O
both O
cell O
types O
. O

By O
contrast O
, O
peritoneal O
fluid O
did O
not O
cause O
significant O
activation O
of O
PPAR B
- I
gamma I
/ I
GAL4 I
constructs I
. O

The O
induction O
of O
IFN B
- I
regulatory I
factor I
- I
1 I
gene I
was O
comparable O
in O
transcription O
level O
in O
uninfected O
and O
infected O
cells O
, O
while O
the O
unidentified O
complex O
formation O
of O
IFN B
- I
regulatory I
factor I
- I
1 I
was O
observed O
in O
infected O
cells O
. O

The O
Drosophila B
FOG I
homologue I
U I
- I
shaped I
( O
Ush B
) O
is O
expressed O
similarly O
in O
the O
blood O
cell O
anlage O
during O
embryogenesis O
. O

Murine B
FOG I
- I
1 I
and I
FOG I
- I
2 I
also O
can O
repress O
crystal O
cell O
production O
, O
but O
a O
mutant O
version O
of O
FOG B
- I
2 I
lacking O
a O
conserved O
motif O
that O
binds O
the O
corepressor B
C I
- I
terminal I
binding I
protein I
fails O
to O
affect O
the O
cell O
lineage O
. O

The O
association O
of O
trans B
- I
acting I
T I
cell I
factors I
( O
TCFs B
) O
or O
lymphoid B
enhancer I
factor I
1 I
( O
LEF B
- I
1 I
) O
with O
their O
coactivator O
beta O
- O
catenin O
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O

Accelerated O
spontaneous O
thymocyte O
death O
in O
the O
absence O
of O
TCF B
- I
1 I
correlates O
with O
aberrantly O
low O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
Bcl B
- I
x I
( I
L I
) I
. O

Furthermore O
, O
suppression O
of O
Akt B
- I
1 I
by O
inhibition O
of O
PI3K B
or O
a O
dominant B
negative I
( I
DN I
) I
Akt I
- I
1 I
resulted O
in O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
activation O
of O
caspases B
- I
9 I
and I
- I
3 I
, O
and O
DNA O
fragmentation O
. O

The O
effects O
of O
PI3K B
inhibition O
were O
reversed O
by O
the O
ectopic O
expression O
of O
constitutively O
activated O
Akt B
- I
1 I
or O
Bcl B
- I
x I
( I
L I
) I
. O

Transcriptional O
regulation O
of O
galectin B
- I
10 I
( O
eosinophil B
Charcot I
- I
Leyden I
crystal I
protein I
) O
: O
a O
GC B
box I
( O
- O
44 O
to O
- O
50 O
) O
controls O
butyric O
acid O
induction O
of O
gene O
expression O
. O

Enzymatically B
modified I
low I
- I
density I
lipoprotein I
( O
E B
- I
LDL I
) O
induces O
rapid O
foam O
cell O
formation O
in O
monocytes O
and O
upregulates O
adipophilin B
mRNA O
and O
protein O
within O
2 O
h O
of O
incubation O
. O

METHODS O
: O
We O
prepared O
immature O
dendritic O
cells O
by O
incubating O
CD14 O
- O
positive O
cells O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
and O
interleukin B
( I
IL I
) I
- I
4 I
. O

This O
defect O
prevents O
the O
proteolytic O
processing O
required O
for O
the O
production O
and O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
plays O
important O
roles O
in O
immune O
and O
inflammatory O
responses O
, O
as O
well O
as O
increases O
the O
susceptibility O
of O
the O
affected O
cells O
to O
apoptosis O
induced O
by O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
. O

Plasma B
monocyte I
chemoattractant I
protein I
- I
1 I
and O
soluble B
intracellular I
adhesion I
molecule I
- I
1 I
concentrations O
did O
not O
decrease O
significantly O
after O
troglitazone O
treatment O
, O
although O
there O
was O
a O
trend O
toward O
inhibition O
. O

Plasma B
monocyte I
chemoattractant I
protein I
- I
1 I
and O
soluble B
intracellular I
adhesion I
molecule I
- I
1 I
concentrations O
did O
not O
decrease O
significantly O
after O
troglitazone O
treatment O
, O
although O
there O
was O
a O
trend O
toward O
inhibition O
. O

Reactive O
oxygen O
species O
generation O
by O
polymorphonuclear O
cells O
and O
MNC O
, O
p47 B
( I
phox I
) I
subunit I
protein I
quantities O
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
levels O
decreased O
significantly O
after O
troglitazone O
intake O
. O

Furthermore O
, O
enhanced O
HIV O
- O
1 O
transcription O
in O
gp34 B
- O
stimulated O
ACH O
- O
2 O
/ O
OX40 O
cells O
was O
dependent O
on O
the O
kappa B
B I
site I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
, O
and O
the O
OX40 O
- O
gp34 O
interaction O
activated O
NF B
- I
kappa I
B I
consisting O
of O
p50 B
and I
p65 I
subunits I
. O

Transient O
transfection O
assays O
of O
the O
human B
osteopontin I
promoter I
/ I
luciferase I
construct I
which O
contains O
a O
5 B
' I
- I
flanking I
region I
between O
- O
1500 O
and O
+ O
87 O
relative O
to O
the O
transcription B
start I
site I
demonstrate O
that O
either O
treatment O
with O
troglitazone O
or O
cotransfection O
of O
PPARgamma B
expression I
vector I
inhibits O
osteopontin O
promoter O
activity O
. O

Transcription B
factor I
NF I
- I
kappa I
B I
regulates O
Ig B
lambda I
light O
chain O
gene O
rearrangement O
. O

In O
response O
to O
IL B
- I
4 I
, O
the O
IL B
- I
4R I
activates O
a O
set O
of O
phosphotyrosine B
binding I
domain I
- I
containing I
proteins I
, O
including O
insulin B
receptor I
substrate I
1 I
/ I
2 I
, O
Shc B
, O
and O
IL B
- I
4R I
interacting I
protein I
, O
as O
well O
as O
Stat6 B
. O

In O
response O
to O
IL B
- I
4 I
, O
the O
IL B
- I
4R I
activates O
a O
set O
of O
phosphotyrosine B
binding I
domain I
- I
containing I
proteins I
, O
including O
insulin B
receptor I
substrate I
1 I
/ I
2 I
, O
Shc B
, O
and O
IL B
- I
4R I
interacting I
protein I
, O
as O
well O
as O
Stat6 B
. O

Both O
WT B
and I
Y497F I
hIL I
- I
4Ralpha I
lose O
the O
ability O
to O
drive O
Th2 O
differentiation O
and O
cell O
expansion O
in O
Stat6 O
- O
knockout O
CD4 O
T O
cells O
. O

Tat B
derepresses O
and O
activates O
the O
distal B
AP I
- I
1 I
site I
( O
position B
- I
185 I
to I
- I
177 I
) O
in O
the O
IL B
- I
2 I
promoter I
. O

OBJECTIVE O
: O
Thrombopoietin B
( O
TPO B
) O
and O
transforming B
growth I
factor I
- I
beta I
( I
1 I
) I
( O
TGF B
- I
beta I
( I
1 I
) I
) O
have O
been O
shown O
to O
exert O
opposite O
effects O
on O
proliferation O
and O
megakaryocytic O
differentiation O
of O
hematopoietic O
cells O
. O

To O
determine O
whether O
TGF B
- I
beta I
( I
1 I
) I
interferes O
directly O
with O
TPO B
- O
induced O
signal O
transduction O
in O
hematopoietic O
cells O
, O
we O
compared O
the O
regulatory O
effects O
in O
the O
TPO B
- O
responsive O
cell O
lines O
Mo O
- O
7e O
and O
HEL O
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

CONCLUSION O
: O
Taken O
together O
, O
these O
data O
suggest O
that O
TGF B
- I
beta1 I
modulates O
TPO B
- O
mediated O
effects O
on O
megakaryocytic O
proliferation O
by O
interfering O
with O
TPO B
- O
induced O
signal O
transduction O
, O
particularly O
by O
reducing O
the O
activities O
of O
MAPK B
ERK1 I
/ I
ERK2 I
and I
STAT5 I
. O

Recently O
, O
invariant B
chain I
( O
Ii B
) O
, O
a O
major B
histocompatibility I
complex I
class I
II I
chaperone I
, O
as O
well O
as O
the O
transcription B
factors I
c B
- I
Rel I
and O
p65 B
/ I
RelA I
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

The O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
a O
member O
of O
the O
nuclear B
hormone I
receptor I
superfamily I
, O
is O
essential O
for O
adipocyte O
differentiation O
and O
glucose O
homeostasis O
. O

A O
prominent O
role O
for O
activator B
protein I
- I
1 I
in O
the O
transcription O
of O
the O
human B
2B4 I
( I
CD244 I
) I
gene I
in O
NK O
cells O
. O

In O
this O
study O
, O
we O
report O
the O
molecular O
cloning O
and O
characterization O
of O
the O
human B
2B4 I
( I
h2B4 I
) I
promoter I
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 B
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

Lymphocyte O
commitment O
and O
differentiation O
are O
accompanied O
by O
programmed O
gene O
expression O
or O
repression O
events O
which O
are O
driven O
by O
lineage B
and I
stage I
specific I
transcription I
factors I
. O

One O
of O
the O
most O
prominent O
glucocorticoid O
- O
induced O
genes B
is O
glucocorticoid B
- I
induced I
leucine I
zipper I
( O
GILZ B
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation O
- O
induced O
up O
- O
regulation O
of O
Fas B
ligand I
( I
FasL I
) I
mRNA I
. O

To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma O
cell O
line O
was O
transfected O
with O
pFL3 B
that O
contains O
the O
TGF B
- I
beta I
- I
responsive I
element I
of O
the O
GLalpha B
promoter I
, O
and O
stimulated O
with O
TGF B
- I
beta1 I
. O

Upon O
B B
cell I
receptor I
( O
BCR B
) O
engagement O
and O
coculture O
with O
activated O
CD4 O
+ O
T O
cells O
, O
these O
lymphocytes O
upregulated O
pol B
zeta I
, O
downregulated O
pol B
eta I
, O
and O
mutated O
the O
Ig B
and I
bcl I
- I
6 I
genes I
. O

Cot B
kinase I
induces O
cyclooxygenase O
- O
2 O
expression O
in O
T O
cells O
through O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
. O

Induction O
of O
COX O
- O
2 O
promoter O
activity O
by O
Cot B
kinase I
occurred O
mainly O
through O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
. O

Members O
of O
the O
Ly B
- I
49 I
gene I
family I
code O
for O
class B
I I
MHC I
- I
specific I
receptors I
that O
regulate O
NK O
cell O
function O
. O

Human B
ACAT I
- I
1 I
gene I
contains O
two O
promoters B
( O
P1 B
and O
P7 B
) O
, O
each O
located O
in O
a O
different O
chromosome B
( I
1 I
and I
7 I
) I
( O
Li O
, O
B O
. O
L O
. O
, O
Li O
, O
X O
. O
L O
. O
, O
Duan O
, O
Z O
. O
J O
. O
, O
Lee O
, O
O O
. O
, O
Lin O
, O
S O
. O
, O
Ma O
, O
Z O
. O
M O
. O
, O
Chang O
, O
C O
. O
C O
. O
, O
Yang O
, O
X O
. O
Y O
. O
, O
Park O
, O
J O
. O
P O
. O
, O
Mohandas O
, O
T O
. O
K O
. O
, O
Noll O
, O
W O
. O
, O
Chan O
, O
L O
. O
, O
and O
Chang O
, O
T O
. O
Y O
. O
( O
1999 O
) O
J O
. O
Biol O
Chem O
. O

To O
examine O
the O
molecular O
nature O
of O
this O
observation O
, O
we O
identified O
within O
the O
ACAT B
- I
1 I
P1 I
promoter I
a O
159 B
- I
base I
pair I
core I
region I
. O

We O
could O
suppress O
GATA O
- O
3 O
expression O
in O
interleukin B
( I
IL I
) I
- I
4 I
- O
producing O
T O
cells O
in O
vitro O
and O
in O
vivo O
by O
an O
antisense O
phosphorothioate O
oligonucleotide O
overlapping O
the O
translation B
start I
site I
of O
GATA B
- I
3 I
, O
whereas O
nonsense O
control O
oligonucleotides O
were O
virtually O
inactive O
. O

Advanced O
glycation O
end O
product O
( O
AGE O
) O
activation O
of O
the O
signal B
- I
transducing I
receptor I
for I
AGE I
( O
RAGE B
) O
has O
been O
linked O
to O
a O
proinflammatory O
phenotypic O
change O
within O
cells O
. O

CML B
- I
modified I
albumin I
produced O
rapid O
transient O
activation O
of O
tyrosine O
phosphorylation O
, O
extracellular B
signal I
- I
regulated I
kinase I
1 I
and I
2 I
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
, O
but O
not O
c B
- I
Jun I
NH I
( I
2 I
) I
- I
terminal I
kinase I
. O

Transcription B
factor I
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
is O
activated O
in O
cerulein O
pancreatitis O
and O
mediates O
cytokine O
expression O
. O

Morphological O
damage O
and O
trypsin O
activation O
were O
much O
greater O
in O
the O
pancreatic O
head O
than O
tail O
, O
in O
parallel O
with O
a O
stronger O
activation O
of O
NF B
- I
kappaB I
and I
cytokine I
mRNA I
. O

Pax5 B
appears O
to O
mediate O
B O
- O
lineage O
commitment O
by O
repressing O
the O
transcription O
of O
non B
- I
B I
- I
lymphoid I
genes I
and O
by O
simultaneously O
activating O
the O
expression O
of O
B B
- I
lineage I
- I
specific I
genes I
. O

Pax5 B
appears O
to O
mediate O
B O
- O
lineage O
commitment O
by O
repressing O
the O
transcription O
of O
non B
- I
B I
- I
lymphoid I
genes I
and O
by O
simultaneously O
activating O
the O
expression O
of O
B B
- I
lineage I
- I
specific I
genes I
. O

Nuclear O
translocation O
of O
NF B
- I
kappaB I
/ I
Rel I
proteins I
coincided O
with O
IkappaBalpha O
degradation O
. O

Proteolysis O
of O
NF O
- O
kappaB O
inhibitors O
was O
apparently O
due O
to O
transient O
activation O
of O
IkappaB B
kinase I
( I
IKK I
) I
beta I
that O
reached O
maximum O
activity O
at O
1 O
hour O
after O
plasmin B
stimulation O
. O

We O
therefore O
investigated O
a O
common O
downstream O
effector O
of O
cytokines B
, O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
. O

METHODS O
: O
Peripheral O
granulocytes O
from O
patients O
with O
P O
. O
vera O
and O
from O
healthy O
volunteers O
were O
assayed O
for O
STAT1 B
, I
3 I
, I
and I
5 I
DNA O
binding O
by O
electrophoretic O
mobility O
shift O
assay O
. O

A O
transcriptional O
block O
in O
the O
IL B
- I
2 I
promoter I
at O
the O
- B
150 I
AP I
- I
1 I
site I
in O
effector O
CD8 O
+ O
T O
cells O
. O

They O
also O
showed O
the O
expression O
of O
mRNA O
for O
the O
myeloid B
- I
specific I
PU I
. I
1 I
but O
did O
not O
that O
for O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
. O

They O
also O
showed O
the O
expression O
of O
mRNA O
for O
the O
myeloid B
- I
specific I
PU I
. I
1 I
but O
did O
not O
that O
for O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
. O

Among O
various O
cytokines B
, O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
induced O
erythroid O
precursor O
cells O
that O
expressed O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
and O
beta B
- I
major I
globin I
. O

Gads B
acts O
by O
linking O
SLP B
- I
76 I
, O
bound O
by O
the O
carboxy B
- I
terminal I
Gads I
SH3 I
domain I
, O
to O
tyrosine B
phosphorylated I
LAT I
which O
contains O
binding O
sites O
for O
the O
Gads B
SH2 I
domain I
. O

EAE O
was O
actively O
induced O
in O
C57BL O
/ O
6 O
mice O
using O
an O
encephalitogenic O
myelin B
oligodendrocyte I
glycoprotein I
( O
MOG B
( I
35 I
- I
55 I
) I
) O
peptide O
. O

T O
- O
cell O
activation O
, O
assessed O
by O
the O
production O
of O
interferon B
gamma I
( O
IFNgamma B
) O
in O
response O
to O
MOG B
( I
35 I
- I
55 I
) I
, O
was O
also O
decreased O
by O
the O
HSR O
. O

This O
approach O
uses O
reporter B
- I
plasmids I
for O
the O
detection O
of O
intracellular O
signals O
mediated O
by O
the O
mitogen B
- I
activated I
protein I
kinase I
or O
cyclic B
AMP I
- I
dependent I
protein I
kinase I
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
is O
the O
non B
- I
DNA I
- I
binding I
subunit I
of O
the O
heterodimeric B
CBFs I
. O

Promoter B
deletion I
analysis I
defined O
a O
minimal B
promoter I
between O
positions B
+ I
52 I
and I
+ I
93 I
base O
pairs O
, O
a O
GC B
- I
rich I
region I
. O

Moreover O
, O
PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
displayed O
reduced O
expression O
of O
the O
receptors O
for O
stem B
cell I
factor I
and O
interleukin B
( I
IL I
) I
- I
7 I
, O
suggesting O
a O
nonredundant O
role O
for O
PU B
. I
1 I
in O
regulating O
the O
expression O
of O
these O
cytokine B
receptor I
genes I
during O
NK O
cell O
development O
. O

We O
used O
several O
agents O
active O
on O
signal O
transduction O
pathways O
in O
cytokine O
expression O
, O
such O
as O
the O
protein O
kinase O
C O
inhibitor O
staurosporin O
, O
antioxidant O
agents O
including O
N O
- O
acetyl O
cysteine O
( O
NAC O
) O
and O
pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
inhibitor O
SB203580 O
. O

Benzene O
- O
extracted O
components O
showed O
effects O
mimicking O
DEPs O
on O
IL O
- O
8 O
gene O
expression O
, O
release O
of O
several O
cytokines B
( O
IL B
- I
8 I
; O
granulocyte B
macrophage I
colony I
- I
stimulating I
factor I
; O
and O
regulated O
on O
activation O
, O
normal O
T O
cells O
expressed O
and O
secreted O
) O
and O
nuclear O
factor O
( O
NF O
) O
- O
kappa O
B O
activation O
. O

Gene O
transfer O
of O
antisense O
hypoxia B
inducible I
factor I
- I
1 I
alpha I
enhances O
the O
therapeutic O
efficacy O
of O
cancer O
immunotherapy O
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 B
- I
Runx2 I
transgene I
either O
with O
a O
Pim1 B
transgene I
( O
E B
( I
mu I
) I
- I
Pim1 I
) O
or O
with O
the O
p53 B
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B
. O

T B
- I
cell I
factor I
- I
1 I
expression O
during O
human O
natural O
killer O
cell O
development O
and O
in O
circulating O
CD56 B
( I
+ I
) I
bright O
natural O
killer O
cells O
. O

We O
found O
that O
fresh O
CD34 O
( O
+ O
) O
Lin O
( O
- O
) O
cells O
that O
are O
human O
leukocyte O
antigen O
( O
HLA O
) O
- O
DR O
( O
- O
) O
or O
CD38 O
( O
- O
) O
constitutively O
express O
GATA B
- I
3 I
but O
not O
T B
- I
cell I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
or O
Id B
- I
3 I
. O

Transcriptional O
activation O
by O
a O
matrix B
associating I
region I
- I
binding I
protein I
. O

Bright B
( O
B B
cell I
regulator I
of I
IgH I
transcription I
) O
is O
a O
B O
cell O
- O
specific O
, O
matrix B
associating I
region I
- I
binding I
protein I
that O
transactivates O
gene O
expression O
from O
the O
IgH B
intronic I
enhancer I
( O
E B
mu I
) O
. O

Bright B
( O
B B
cell I
regulator I
of I
IgH I
transcription I
) O
is O
a O
B O
cell O
- O
specific O
, O
matrix B
associating I
region I
- I
binding I
protein I
that O
transactivates O
gene O
expression O
from O
the O
IgH B
intronic I
enhancer I
( O
E B
mu I
) O
. O

Translocations O
of O
the O
BCL B
- I
6 I
gene I
to O
heterologous B
promoters I
and O
mutations O
of O
its O
5 B
' I
- I
noncoding I
regulatory I
region I
were O
reported O
to O
be O
potential O
mechanisms O
for O
deregulating O
BCL B
- I
6 I
expression O
and O
for O
playing O
a O
role O
in O
the O
genesis O
of O
non O
- O
Hodgkin O
lymphoma O
. O

Here O
we O
show O
that O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
Gadd45gamma B
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B
kinase I
Jak3 I
and O
the O
transcription B
factors I
Stat5a B
and O
Stat5b B
( O
signal B
transducer I
and I
activator I
of I
transcription I
) O
. O

Regulation O
of O
the O
helix B
- I
loop I
- I
helix I
proteins I
, O
E2A B
and O
Id3 B
, O
by O
the O
Ras B
- O
ERK B
MAPK B
cascade O
. O

To O
test O
this O
hypothesis O
, O
we O
targeted O
SHP B
- I
1 I
into O
lipid O
rafts O
by O
using O
the O
N B
- I
terminal I
region I
of I
Lck I
( O
residues B
1 I
- I
- I
14 I
) O
. O

The O
results O
indicate O
that O
the O
expression O
of O
Lck B
/ I
SHP I
- I
1 I
chimera I
inside O
lipid O
rafts O
profoundly O
inhibits O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
CD3 B
zeta I
/ I
epsilon I
, O
IL O
- O
2 O
generation O
, O
and O
nuclear O
mobilization O
of O
NF B
- I
AT I
. O

Although O
interleukin B
( I
IL I
) I
- I
12 I
and O
IL B
- I
4 I
polarize O
naive O
CD4 O
( O
+ O
) O
T O
cells O
toward O
T O
helper O
cell O
type O
1 O
( O
Th1 O
) O
or O
Th2 O
phenotypes O
, O
it O
is O
not O
known O
whether O
cytokines B
instruct O
the O
developmental O
fate O
in O
uncommitted O
progenitors O
or O
select O
for O
outgrowth O
of O
cells O
that O
have O
stochastically O
committed O
to O
a O
particular O
fate O
. O

Monocytes O
are O
extremely O
important O
cells O
for O
regulating O
the O
cytokine O
network O
and O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
and O
interleukin B
- I
( I
IL I
) I
10 I
, O
which O
are O
mainly O
synthesized O
by O
monocytes O
, O
are O
representative O
cytokines B
that O
play O
a O
central O
role O
in O
the O
cytokine O
network O
. O

In O
this O
study O
, O
we O
have O
explored O
the O
roles O
of O
the O
second O
messenger O
NO O
and O
the O
transcription B
factor I
NF I
- I
kappa I
B I
in O
SDF1 B
alpha I
- O
induced O
T O
cell O
migration O
. O

Furthermore O
, O
we O
observed O
that O
inhibitors O
of O
the O
transcription B
factor I
NF I
- I
kappa I
B I
, O
which O
is O
linked O
to O
NO O
signaling O
pathways O
, O
also O
significantly O
blocked O
the O
SDF1 B
alpha I
- O
induced O
chemotactic O
response O
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR B
transgene I
, O
dominant B
negative I
ras I
/ I
Mek I
proteins I
and O
a O
reporter B
gene I
construct I
with O
AP B
- I
1 I
or I
NF I
- I
kappa I
B I
binding I
sites I
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
but O
not O
AP B
- I
1 I
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

In O
contrast O
, O
we O
found O
a O
complete O
lack O
of O
constitutive O
expression O
of O
the O
epsilon B
isoform I
of I
Protein I
Kinase I
C I
( O
PKC B
) O
in O
DP O
thymocytes O
, O
although O
it O
was O
present O
in O
mature O
thymocytes O
and O
peripheral O
T O
cells O
. O

As O
was O
previously O
reported O
for O
the O
HSV B
- I
1 I
ICP0 I
and I
CMV I
IE1 I
proteins I
, O
Z B
reduces O
the O
amount O
of O
SUMO B
- I
1 I
- I
modified I
PML I
. O

We O
measured O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
inhibitor B
kappaB I
( I
IkappaB I
) I
alpha I
, O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
, O
and O
p47 B
( I
phox I
) I
subunit I
( O
a O
key O
component O
protein O
of O
nicotinamide B
adenine I
dinucleotide I
phosphate I
oxidase I
) O
in O
MNC O
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

Phosphorylation O
of O
the O
N B
- I
terminal I
domain I
of O
I B
kappa I
B I
inhibitory I
subunits I
induces O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappa I
B I
. O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

Nevertheless O
, O
innate O
immunity O
is O
preserved O
in O
XHM O
- O
ED O
patients O
because O
APCs O
retain O
the O
capacity O
to O
respond O
to O
stimulation O
by O
lipopolysaccharide O
or O
Staphylococcus B
aureus I
Cowan I
' I
s I
antigen I
( O
SAC B
) O
. O

APL O
diagnostic O
t O
( O
15 O
; O
17 O
) O
chromosomal O
translocation O
and O
expresses O
the O
PML B
- I
RAR I
alpha I
fusion I
protein I
. O

ATRA O
and O
its O
metabolites O
could O
induce O
NB4 O
cells O
differentiation O
with O
similar O
activity O
, O
as O
evaluated O
by O
cell O
morphology O
, O
by O
the O
nitroblue O
tetrazolium O
reduction O
test O
( O
82 O
- O
88 O
% O
at O
120 O
h O
) O
or O
by O
the O
expression O
of O
the O
maturation B
specific I
cell I
surface I
marker I
CD11c I
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

This O
study O
is O
the O
first O
in O
which O
concentrations O
of O
ASA O
in O
the O
therapeutic O
range O
were O
found O
to O
significantly O
reduce O
interleukin B
( I
IL I
) I
- I
4 I
secretion O
and O
RNA O
expression O
in O
freshly O
isolated O
and O
mitogen O
- O
primed O
human O
CD4 O
+ O
T O
cells O
. O

The O
NF B
- I
kappaB I
/ I
Rel I
family I
represents O
one O
signal O
transduction O
pathway O
induced O
during O
such O
activation O
. O

In O
contrast O
, O
inclusion O
of O
both O
G B
- I
CSF I
and O
hydrocortisone O
in O
the O
cytokine B
` I
` I
cocktail I
' I
' I
markedly O
increased O
the O
neutrophil O
numbers O
. O

The O
optimal O
activation O
of O
cAMP B
- I
responsive I
element I
binding I
protein I
( O
CREB B
) O
, O
similar O
to O
the O
full O
activation O
of O
T O
lymphocytes O
, O
requires O
the O
stimulation O
of O
both O
CD3 B
and O
CD28 B
. O

CD3 B
/ I
CD28 I
- O
promoted O
CREB B
- O
CBP B
interaction O
was O
dependent O
on O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( I
CaMK I
) I
IV I
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

The O
murine B
IL I
- I
2 I
promoter I
contains O
distal B
regulatory I
elements I
responsive O
to O
the O
Ah B
receptor I
, O
a O
member O
of O
the O
evolutionarily O
conserved O
bHLH B
- I
PAS I
transcription I
factor I
family I
. O

Visualization O
of O
Syk B
- I
antigen I
receptor I
interactions O
using O
green B
fluorescent I
protein I
: O
differential O
roles O
for O
Syk B
and O
Lyn B
in O
the O
regulation O
of O
receptor O
capping O
and O
internalization O
. O

Neoplastic O
T O
lymphocytes O
from O
22 O
of O
24 O
cases O
of O
MF O
showed O
strong O
nuclear O
and O
cytoplasmic O
expression O
of O
active B
p65 I
( I
Rel I
A I
) I
. O

We O
examined O
the O
activity O
of O
Tax B
in O
transcription O
through O
AP B
- I
1 I
- I
binding I
sites I
( O
AP B
- I
1 I
site I
) O
in O
T O
cells O
. O

Thus O
, O
Tax B
seems O
to O
activate O
the O
AP B
- I
1 I
site I
via O
mechanisms O
distinct O
from O
those O
of O
kappaB B
or I
CRE I
- I
like I
elements I
, O
and O
the O
activation O
of O
the O
AP B
- I
1 I
site I
is O
dispensable O
for O
IL O
- O
2 O
- O
independent O
growth O
of O
CTLL O
- O
2 O
. O

Our O
results O
suggest O
that O
Tax B
activates O
the O
transcription O
of O
cellular B
genes I
with O
AP B
- I
1 I
sites I
by O
inducing O
the O
DNA O
- O
binding O
activity O
of O
AP B
- I
1 I
proteins I
in O
T O
cells O
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE B
- I
like I
and I
kappaB I
elements I
. O

Nuclear O
extracts O
prepared O
from O
the O
Mono O
Mac O
6 O
cells O
and O
RA O
synovial O
tissue O
were O
analyzed O
by O
electrophoretic O
mobility O
shift O
analysis O
( O
EMSA O
) O
for O
NF B
- I
kappaB I
DNA I
binding I
proteins I
. O

A O
NF B
- I
kappaB I
- I
binding I
complex I
with O
similar O
slow O
mobility O
was O
observed O
in O
nuclear O
extracts O
prepared O
from O
fresh O
human O
RA O
synovial O
tissue O
. O

CONCLUSION O
: O
Biological O
activity O
of O
TNF B
- I
alpha I
in O
SF O
from O
RA O
and O
OA O
subjects O
is O
capable O
of O
inducing O
p65 B
/ I
p50 I
NF I
- I
kappaB I
DNA O
binding O
activity O
in O
macrophages O
. O

A O
property O
of O
SF O
that O
is O
independent O
of O
TNF B
- I
alpha I
and O
other O
cytokines B
is O
responsible O
for O
the O
induction O
of O
a O
novel O
slowly O
migrating O
NF B
- I
kappaB I
- I
binding I
complex I
. O

Peroxisome B
proliferator I
activator I
receptor I
- I
gamma I
agonists O
and O
15 O
- O
deoxy O
- O
Delta O
( O
12 O
, O
14 O
) O
( O
12 O
, O
14 O
) O
- O
PGJ O
( O
2 O
) O
induce O
apoptosis O
in O
normal O
and O
malignant O
B O
- O
lineage O
cells O
. O

The O
expression O
of O
almost O
all O
of O
the O
cytokines B
produced O
by O
eosinophils O
, O
including O
the O
proallergic B
cytokine I
IL I
- I
4 I
, O
is O
now O
known O
to O
be O
regulated O
at O
the O
level O
of O
transcription O
by O
members O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
family O
of O
transcription O
factors O
. O

A O
brief O
incubation O
with O
the O
T B
( I
H I
) I
2 I
cytokines I
IL B
- I
4 I
and O
IL B
- I
5 I
was O
sufficient O
to O
induce O
the O
nuclear O
translocation O
of O
NFATc B
. O

It O
is O
composed O
of O
a O
fusion O
between O
full B
- I
length I
Nef I
and O
the O
estrogen B
receptor I
hormone I
- I
binding I
domain I
( O
Nef B
- I
ER I
) O
. O

Here O
we O
show O
that O
T O
- O
cell O
production O
of O
interferon B
( I
IFN I
) I
- I
gamma I
strongly O
suppresses O
osteoclastogenesis O
by O
interfering O
with O
the O
RANKL B
- O
RANK O
signalling O
pathway O
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl B
- I
inositol I
3 I
- I
kinase I
( O
PI B
- I
3K I
) O
by O
LY294002 O
in O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP B
- I
9 I
and O
VEGF B
, O
the O
inhibition O
of O
MAPK B
p42 I
/ I
44 I
( O
by O
the O
MEK O
inhibitor O
U0126 O
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these O
cells O
. O

Adhesion O
of O
immature O
and O
mature O
T O
cells O
induces O
in O
human O
thymic O
epithelial O
cells O
( O
TEC O
) O
activation O
of O
IL B
- I
6 I
gene I
trascription I
factors I
( O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
) O
and O
IL O
- O
6 O
gene O
expression O
: O
role O
of O
alpha3beta1 B
and I
alpha6beta4 I
integrins I
. O

Identification O
and O
characterization O
of O
SKAT B
- I
2 I
, O
a O
novel O
Th2 B
- I
specific I
zinc I
finger I
gene I
. O

Activation O
of O
oncogenic B
transcription I
factor I
AP I
- I
1 I
in O
T O
cells O
infected O
with O
human O
T O
cell O
leukemia O
virus O
type O
1 O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
ability O
of O
Tax B
to O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
( O
AP B
- I
1 I
site I
) O
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B
can O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP B
- I
1 I
proteins I
did O
so O
much O
less O
than O
Tax B
, O
indicating O
that O
the O
activation O
of O
the O
AP B
- I
1 I
site I
by O
Tax B
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP B
- I
1 I
mRNA I
. O

Cyclic O
AMP O
activates O
p38 B
mitogen I
- I
activated I
protein I
kinase I
in O
Th2 O
cells O
: O
phosphorylation O
of O
GATA B
- I
3 I
and O
stimulation O
of O
Th2 O
cytokine O
gene O
expression O
. O

Instead O
, O
cAMP O
stimulates O
activation O
of O
p38 B
mitogen I
- I
activated I
protein I
kinase I
in O
Th2 O
cells O
. O

Thus O
, O
Th2 O
- O
specific O
GATA B
- I
3 I
expression O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
activation O
together O
provide O
a O
molecular O
basis O
for O
the O
differential O
effects O
of O
cAMP O
in O
the O
two O
T O
helper O
cell O
subsets O
. O

In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types O
of O
human B
IL I
- I
13R I
alpha I
1 I
, O
and O
analyzed O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
using O
an O
IL B
- I
13R I
alpha I
1 I
- O
transfected O
human O
B O
cell O
line O
. O

The O
expression O
of O
constitutively O
active O
MAP B
/ I
ERK I
kinase I
kinase I
1 I
( O
MEKK1 B
) O
inhibited O
RXRE O
- O
dependent O
transcription O
, O
whereas O
dominant B
negative I
MEKK1 I
increased O
the O
transcription O
, O
indicating O
the O
involvement O
of O
JNK B
signaling O
pathways O
in O
the O
process O
. O

Therefore O
, O
a O
functional O
proteasome B
is O
required O
for O
optimal O
endocytosis O
of O
the O
IL B
- I
2R I
/ I
ligand I
complex I
and O
is O
essential O
for O
the O
subsequent O
lysosomal O
degradation O
of O
IL B
- I
2 I
, O
possibly O
by O
regulating O
trafficking O
to O
the O
lysosome O
. O

Functional O
characterization O
of O
the O
two O
alternative O
promoters O
of O
human B
p45 I
NF I
- I
E2 I
gene I
. O

Anti B
- I
GM I
- I
CSF I
antibodies I
inhibited O
the O
TNF B
- I
alpha I
- O
induced O
growth O
, O
suggesting O
the O
presence O
of O
an O
autocrine O
loop O
for O
cell O
proliferation O
mediated O
by O
GM B
- I
CSF I
. O

One O
mechanism O
by O
which O
glucocorticoids O
could O
exert O
their O
anti O
- O
inflammatory O
action O
is O
via O
rapidly O
saturable O
, O
stereo B
- I
specific I
cytoplasmic I
protein I
receptors I
. O

The O
predominant O
inducible O
form O
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
is O
a O
heteromeric B
complex I
containing O
two O
Rel B
- I
related I
DNA I
- I
binding I
subunits I
, O
termed B
p65 I
and O
p50 B
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane B
Ig I
. O

While O
mitogenic O
doses O
of O
Fab B
' I
2 I
anti I
- I
Ig I
induce O
large O
and O
rapid O
increases O
in O
Egr O
- O
1 O
expression O
, O
IgG B
anti I
- I
Ig I
results O
in O
smaller O
increases O
in O
Egr B
- I
1 I
mRNA I
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

While O
mitogenic O
doses O
of O
Fab B
' I
2 I
anti I
- I
Ig I
induce O
large O
and O
rapid O
increases O
in O
Egr O
- O
1 O
expression O
, O
IgG B
anti I
- I
Ig I
results O
in O
smaller O
increases O
in O
Egr B
- I
1 I
mRNA I
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

However O
, O
the O
correlation O
between O
Egr O
- O
1 O
expression O
and O
B O
cell O
proliferation O
breaks O
down O
when O
IL B
- I
4 I
is O
added O
as O
a O
co O
- O
mitogen O
to O
induce O
B O
cell O
proliferation O
with O
IgG B
anti I
- I
Ig I
or O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

We O
have O
identified O
a O
human B
TNF I
- I
alpha I
promoter I
element I
, O
kappa B
3 I
, O
which O
plays O
a O
key O
role O
in O
the O
calcium O
- O
mediated O
inducibility O
and O
CsA O
sensitivity O
of O
the O
gene O
. O

We O
have O
previously O
shown O
that O
a O
fragment O
containing O
bp B
- I
95 I
to I
+ I
27 I
of O
the O
mouse B
GM I
- I
CSF I
promoter I
can O
confer O
inducibility O
to O
reporter B
genes I
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

Here O
we O
use O
an O
in O
vitro O
transcription O
system O
to O
demonstrate O
that O
a O
cis B
- I
acting I
element I
( O
positions B
- I
54 I
to I
- I
40 I
) O
, O
referred O
to O
as O
CLE0 B
, O
is O
a O
target O
for O
the O
induction O
signals O
. O

By O
using O
a O
reporter O
- O
based O
expression O
approach O
, O
a O
T B
- I
cell I
- I
specific I
enhancer I
was O
identified O
by O
its O
close O
association O
with O
a O
prominent O
T B
- I
cell I
- I
restricted I
hypersensitive I
sites I
in O
the O
last O
intron O
of O
the O
CD8 B
alpha I
gene I
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 B
- I
bp I
fragment I
( O
bp B
- I
319 I
to I
- I
270 I
) O
that O
included O
a O
potential B
binding I
site I
for O
AP B
- I
1 I
transcription I
factors I
6 O
bp O
upstream O
of O
a O
binding B
site I
for I
Elf I
- I
1 I
, O
a O
member O
of O
the O
Ets B
family I
of O
transcription B
factors I
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 B
- I
bp I
fragment I
( O
bp B
- I
319 I
to I
- I
270 I
) O
that O
included O
a O
potential B
binding I
site I
for O
AP B
- I
1 I
transcription I
factors I
6 O
bp O
upstream O
of O
a O
binding B
site I
for I
Elf I
- I
1 I
, O
a O
member O
of O
the O
Ets B
family I
of O
transcription B
factors I
. O

Moreover O
, O
addition O
of O
anti O
- O
Jun O
family O
antiserum O
in O
electrophoretic O
mobility O
shift O
assay O
reactions O
completely O
blocked O
formation O
of O
the O
AP B
- I
1 I
- I
related I
complexes I
. O

Transient O
transfection O
studies O
in O
MLA O
- O
144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP B
- I
1 I
site I
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf B
- I
1 I
site I
or O
the O
NF B
- I
IL I
- I
3 I
site I
, O
a O
previously O
described O
nuclear B
protein I
binding I
site I
( O
bp B
. I
- I
155 I
to I
- I
148 I
) O
in O
the O
IL B
- I
3 I
promoter I
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild O
- O
type O
constructs O
. O

We O
located O
the O
transcription B
initiation I
site I
and O
showed O
that O
the O
CD4 B
core I
promoter I
( O
positions B
- I
40 I
to I
+ I
16 I
) O
lacks O
a O
classical O
` O
` O
TATA O
' O
' O
or O
initiator B
positioning I
consensus I
sequence I
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian B
virus I
40 I
enhancer I
. O

Comparing O
regions O
of O
the O
Epstein B
- I
Barr I
virus I
ZEBRA I
protein I
which O
function O
as O
transcriptional B
activating I
sequences I
in O
Saccharomyces O
cerevisiae O
and O
in O
B O
cells O
. O

The O
ZEBRA B
protein I
activates O
expression O
of O
Epstein O
- O
Barr O
virus O
early B
- I
lytic I
- I
cycle I
genes I
in O
human O
B O
lymphocytes O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

We O
also O
demonstrate O
that O
TPB B
interaction O
with O
Rel B
activation I
regions I
leads O
to O
synergistic O
activation O
of O
transcription O
of O
a O
kappa B
B I
- I
linked I
reporter I
gene I
. O

Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL B
- I
2B I
binding I
site I
indicated O
that O
IL B
- I
4 I
inhibited O
the O
NFIL B
- I
2B I
complex I
and O
that O
the O
NFIL B
- I
2B I
DNA I
binding I
factor I
is O
distinct O
from O
AP B
- I
1 O
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
stored O
in O
the O
cytoplasm O
in O
complexes O
with O
the O
inhibitor B
protein I
I I
kappa I
B I
alpha I
. O

Identification O
of O
a O
killer B
cell I
- I
specific I
regulatory I
element I
of O
the O
mouse B
perforin I
gene I
: O
an O
Ets O
- O
binding O
site O
- O
homologous O
motif O
that O
interacts O
with O
Ets B
- I
related I
proteins I
. O

A O
region O
extending O
from O
residues B
+ I
62 I
through I
- I
141 I
, O
which O
possesses O
the O
essential O
promoter O
activity O
, O
and O
regions O
further O
upstream O
, O
which O
are O
able O
to O
either O
enhance O
or O
suppress O
gene O
expression O
, O
were O
identified O
. O

The O
region O
between O
residues B
- I
411 I
and I
- I
566 I
was O
chosen O
for O
further O
characterization O
, O
since O
it O
contains O
an O
enhancer O
- O
like O
activity O
. O

We O
have O
identified O
a O
32 O
- O
mer O
sequence O
( O
residues B
- I
491 I
to I
- I
522 I
) O
which O
appeared O
to O
be O
capable O
of O
enhancing O
gene O
expression O
in O
a O
killer O
cell O
- O
specific O
manner O
. O

Within O
this O
segment O
, O
a O
9 O
- O
mer O
motif O
( O
5 O
' O
- O
ACAGGAAGT O
- O
3 O
' O
, O
residues B
- I
505 I
to I
- I
497 I
; O
designated O
NF O
- O
P O
motif O
) O
, O
which O
is O
highly O
homologous O
to O
the O
Ets B
proto I
- I
oncoprotein I
- I
binding I
site I
, O
was O
found O
to O
interact O
with O
two O
proteins O
, O
NF B
- I
P1 I
and O
NF B
- I
P2 I
. O

However O
, O
the O
larger O
native O
molecular O
mass O
of O
NF B
- I
P1 I
suggests O
that O
NF B
- I
P1 I
contains O
an O
additional O
non B
- I
DNA I
- I
binding I
subunit I
( O
s O
) O
. O

The O
transcription B
factor I
NF I
- I
kappa I
B I
participates O
in O
the O
regulation O
of O
both O
IL B
- I
2 I
and I
IL I
- I
2R I
alpha I
genes I
, O
as O
well O
as O
multiple B
cellular I
genes I
involved O
in O
T O
- O
cell O
proliferation O
. O

As O
the O
role O
of O
p50 B
remains O
unclear O
, O
we O
focused O
our O
present O
study O
on O
NF B
- I
kappa I
B1 I
( O
p50 B
/ I
p105 I
) O
gene O
regulation O
. O

Partial O
inhibition O
of O
p50 O
and O
p105 O
expression O
by O
NF B
- I
kappa I
B1 I
antisense O
oligonucleotides O
significantly O
reduced O
T O
- O
cell O
proliferation O
and O
CD25 B
/ I
IL I
- I
2R I
alpha I
cell O
surface O
expression O
. O

In O
T O
lymphoma O
cells O
, O
the O
activity O
of O
the O
Il B
- I
4 I
promoter I
/ I
enhancer I
is O
stimulated O
by O
phorbol O
esters O
, O
Ca O
+ O
+ O
ionophores O
and O
agonists O
of O
protein B
kinase I
A I
and O
inhibited O
by O
low O
doses O
of O
the O
immunosuppressant O
cyclosporin O
A O
. O

The O
Il B
- I
4 I
promoter I
/ I
enhancer I
is O
transcriptionally O
inactive O
in O
B O
lymphoma O
cells O
and O
HeLa O
cells O
. O

DNase O
I O
footprint O
protection O
experiments O
revealed O
six O
sites O
of O
the O
Il B
- I
4 I
promoter I
/ I
enhancer I
to O
be O
bound O
by O
nuclear B
proteins I
from O
lymphoid O
and O
myeloid O
cells O
. O

However O
, O
addition O
of O
a O
phosphatidylinositol B
- I
specific I
PLC I
from O
B O
. O
cereus O
also O
induced O
diacylglycerol O
but O
did O
not O
activate O
kappa B
B I
enhancer I
- I
directed I
vectors I
. O

In O
addition O
, O
Scatchard O
plot O
analysis O
of O
125I B
- I
labeled I
IL I
- I
2 I
showed O
that O
Dex O
did O
not O
affect O
the O
binding O
of O
IL B
- I
2 I
, O
thus O
suggesting O
that O
inhibition O
is O
due O
to O
a O
postreceptor O
effect O
. O

To O
determine O
what O
type O
of O
synovial O
cell O
was O
positive O
for O
EBS O
, O
cryosections O
of O
synovial O
tissues O
were O
immunostained O
with O
a O
specific O
monoclonal B
anti I
- I
estrogen I
receptor I
antibody I
( O
anti B
- I
ER I
MAb I
) O
using O
both O
immunofluorescence O
and O
immunoperoxidase O
techniques O
. O

